U.S. Machinery Stock News

Earlier in 2025, the California Public Utilities Commission voted 4–1 to let San Diego Gas & Electric and Southern California Gas, owned by Sempra, keep allowed profit margins around 10% for 2026, despite pressure from consumer advocates for much lower levels. This decision shores up visibility on future returns for Sempra’s California utilities while highlighting ongoing political tension over energy affordability and utility profitability. We’ll now examine how securing roughly 10% allowed...

Sociedad Química y Minera de Chile recently returned to profitability with US$407.8 million in net income for the nine months to September 30, 2025, completed a US$125.7 million acquisition of Sichuan Dixin’s 20,000‑ton lithium hydroxide plant, and agreed a new profit‑sharing joint venture with Codelco over the Salar de Atacama. China’s revocation of multiple lithium mining licenses has tightened supply and pushed local prices higher, which enhances the importance of SQM’s low‑cost global...

In the past week, RingCentral reported quarterly revenue of US$638.7 million, growing 4.9% year on year and meeting analyst expectations, but issued revenue guidance for the next quarter that fell well short of forecasts. While management highlighted solid execution, expanding margins, and strong free cash flow, the weaker forward guidance raised fresh questions about the pace of RingCentral’s growth as AI-related investment and competition intensify. Next, we’ll explore how RingCentral’s...

If you are wondering whether Lam Research is still worth buying after its huge run, you are not alone. This breakdown will help you cut through the noise. The stock has climbed 2.6% over the last week, 10.7% over the past month, and is up an eye catching 127.4% year to date. It has recorded a staggering 131.5% gain over 1 year and 312.4% over 3 years, which hints at strong momentum but also rising expectations. Recently, Lam has stayed in the spotlight as investors double down on chip...

If you are wondering whether EchoStar’s explosive run still has room to continue, or if the market has already priced in the story, you are not alone. This is exactly where a closer look at valuation comes in. After a massive 350.9% year to date gain and 353.7% rise over the last year, the stock has recently cooled off a bit, with a 1.7% pullback over the past week. This could signal either a healthy breather or early profit taking. Recent headlines have focused on EchoStar’s strategic...

Earlier this week, Skyward Specialty Insurance Group, Inc. and AI underwriting firm Sixfold announced a partnership to accelerate AI-powered underwriting across Skyward’s U.S. property and casualty lines, with Sixfold’s platform already deployed in six business units and more than 10 product lines. The rapid 8–10 week rollout timeline and broad deployment underscore how quickly Skyward is embedding AI into core underwriting workflows to enhance data-driven decisions and efficiency. We’ll now...

In mid-December 2025, Yelp’s Chief Financial Officer David Schwarzbach sold 13,500 company shares, adding to a year-long pattern of insider sales with no corresponding insider purchases. This steady stream of insider selling activity may influence how investors interpret leadership confidence in Yelp’s prospects, especially alongside mixed operational signals. We’ll now examine how this pattern of insider selling could influence Yelp’s existing investment narrative and the way investors...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

MiMedx Group recently published new peer-reviewed data in the Journal of Inflammation showing that its Purion-processed DHACM and LHACM placental allografts exert multifactorial immunomodulatory effects on key inflammatory cells involved in wound healing. The findings that these allografts both temper inflammatory monocyte and macrophage activity and enhance pro-reparative functions such as efferocytosis and cell survival could strengthen the medical community’s confidence in MiMedx’s...

PAR Technology (PAR) is back in the spotlight after Wasatch Global Investors exited its position, citing weaker than expected organic growth, just as the company leans on new products like Smart Passes to reset its story. See our latest analysis for PAR Technology. That backdrop helps explain why, even with a recent 1 month share price return of about 8 percent and a 1 day gain of nearly 3 percent to 36.83 dollars, PAR’s year to date share price return is still deep in the red. Its 1 year...

Anywhere Real Estate (HOUS) is back on investors radar after a series of upbeat calls from Keefe, Bruyette & Woods, Barclays, and JP Morgan, signaling improving confidence in its residential brokerage and franchise operations. See our latest analysis for Anywhere Real Estate. Those upbeat calls land at a time when momentum is clearly building, with Anywhere Real Estate’s share price up sharply over the past quarter and its year to date share price return far outpacing its already impressive 1...

GoDaddy (GDDY) has quietly slipped this year, with the stock down around 36% year to date despite solid revenue and earnings growth, and that disconnect is exactly what has investors rechecking their assumptions. See our latest analysis for GoDaddy. Despite the drop, the 1 day and 7 day share price returns have turned positive, and that small change in tone sits against a still healthy three year total shareholder return of nearly 70%. This suggests long term holders have been well rewarded...

If you have been wondering whether KBR is a beaten down opportunity or a value trap, you are not alone. This article is going to walk through the numbers with you. After sliding to around $42.80, the stock is down 1.6% over the last week and up 5.7% over 30 days, but still sitting on a heavy year-to-date loss of 26.1% and a 23.9% drop over the past year, despite being up 51.8% over five years. That kind of whiplash performance has come alongside a steady stream of contract wins and strategic...

In recent coverage, Mizuho and Citi both initiated positive ratings on Spyre Therapeutics, highlighting its half-life extended monoclonal antibody pipeline for inflammatory bowel and other autoimmune diseases. Analysts emphasized Spyre’s ability to explore novel antibody combinations and its rheumatic disease program, with several firms now expressing broad confidence in the company’s development approach. We’ll now explore how this wave of optimistic analyst coverage, particularly around...

Expand Energy (EXE) just released a standout earnings update, with adjusted EPS jumping sharply year over year on stronger oil, gas, and NGL sales, plus sizable contributions from marketing and derivatives. See our latest analysis for Expand Energy. Even after this blowout quarter, the stock has cooled off recently, with a 30 day share price return of minus 8.1 percent. However, a 1 year total shareholder return of 17.2 percent still signals that momentum is building over the longer run. If...

HeartFlow (HTFL) has climbed about 9% in a day and 8% over the past week, an eye catching move for a relatively young medtech stock. Investors are asking whether this momentum is sustainable. See our latest analysis for HeartFlow. The latest surge comes after a choppy few months, with a 30 day share price return of 5.21% but a 90 day share price return still in negative territory, suggesting momentum is only just starting to rebuild. If HeartFlow's recent move has your attention, it could be...

Trevi Therapeutics (TRVI) just named veteran finance executive David Hastings as its next Chief Financial Officer, effective January 6, 2026, a move that immediately sharpened investor focus on the stock’s trajectory. See our latest analysis for Trevi Therapeutics. The timing of Hastings’ appointment coincides with Trevi’s 90-day share price return of nearly 50 percent and roughly 180 percent year-to-date share price gain, which together indicate firmly building momentum, supported by a...

Chimera Investment Corporation’s board declared a fourth-quarter cash dividend of US$0.37 per common share, payable on January 30, 2026, to shareholders of record as of the December 31, 2025 ex-dividend date. This dividend decision sheds light on Chimera’s ongoing approach to distributing income from its diversified mortgage asset portfolio, a key focus for income-oriented investors. We’ll now explore how this latest dividend declaration shapes Chimera Investment’s broader investment...

Earlier this week, Sphere Entertainment announced that veteran entertainment technologist Felicia Yue has joined as Executive Vice President and Chief Technology Officer, where she will oversee the advanced display, playback, interactive, and audio systems underpinning the company’s immersive Sphere venues and Sphere Studios. Her track record building widely used broadcast technologies like the NFL’s yellow 1st‑down line and CNN’s election “Magic Wall” underscores Sphere’s push to deepen its...

ANI Pharmaceuticals (ANIP) has quietly kept its momentum, with shares edging higher over the past week and delivering strong gains this year. That strength invites a closer look at what is driving the move. See our latest analysis for ANI Pharmaceuticals. With the share price now at $82.83, the recent 7 day share price return of just over 3 percent sits against a much stronger year to date share price return and a standout multi year total shareholder return record. This suggests positive...

As the U.S. stock market experiences a resurgence, with major indices like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities that may arise from these fluctuations. In such an environment, identifying undervalued stocks can be crucial for those looking to capitalize on potential growth while maintaining a balanced portfolio amidst shifting market dynamics.

As the U.S. stock market experiences a surge, particularly in tech shares, investors are closely monitoring growth companies with high insider ownership as potential opportunities amidst this renewed risk appetite. In such an environment, stocks that combine robust earnings growth with significant insider stakes can offer insights into management confidence and alignment with shareholder interests.

Major stock indexes in the United States have recently experienced a surge, driven by gains in technology shares and positive economic indicators. While the term "penny stocks" might seem outdated, it still refers to shares of smaller or newer companies that can offer significant potential for growth. By focusing on those with solid financial foundations, investors can uncover opportunities that may provide stability and upside potential.

As the U.S. market navigates a landscape marked by surging tech shares and volatile index movements, investors are keenly observing how these dynamics impact small-cap stocks, particularly within the S&P 600. With major indices like the Nasdaq and S&P 500 experiencing gains driven by AI-related optimism, identifying lesser-known stocks with strong fundamentals can be key to capitalizing on potential growth opportunities amidst broader market shifts.